Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $276
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated LGND | 0.00 |
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:
LGND) with a Buy and raises the price target from $270 to $276.